| Literature DB >> 32646721 |
William A Zoghbi1, Marcelo F DiCarli2, Ron Blankstein2, Andrew D Choi3, Vasken Dilsizian4, Frank A Flachskampf5, Jeffrey B Geske6, Paul A Grayburn7, Farouc A Jaffer8, Raymond Y Kwong2, Jonathan A Leipsic9, Thomas H Marwick10, Eike Nagel11, Koen Nieman12, Subha V Raman13, Michael Salerno14, Partho P Sengupta15, Leslee J Shaw16, Y S Chandrashekhar17.
Abstract
Entities:
Keywords: COVID-19; cardiac computer tomography; cardiac magnetic resonance; cardiovascular imaging; echocardiography; nuclear cardiology
Mesh:
Year: 2020 PMID: 32646721 PMCID: PMC7290215 DOI: 10.1016/j.jcmg.2020.06.001
Source DB: PubMed Journal: JACC Cardiovasc Imaging ISSN: 1876-7591
Balancing Safety and Patient Care in the COVID-19 Era
Practice hand hygiene and social distancing in public and in waiting rooms, limit accompanying visitors (0–1), wear masks. Shorten contact time in laboratories (not at expense of quality). Keep needed personnel and equipment in the testing room at a minimum. Institute antiviral sanitation of rooms and equipment between studies and at the end of the day. |
Administer health screening of patients and professionals (symptoms, temperature check). Practice hand hygiene and social distancing, wear masks. Use appropriate PPE for the imaging lab and for tests being performed. Strongly consider testing for COVID-19 before TEE and possibly before exercise stress, as available. Perform aerosol-generating procedures preferably in a dedicated, negative-pressure room with good air circulation. |
Use appropriate testing that emphasizes impact on health and clinical management. Choose the best test that provides essential information for the clinical condition. Avoid layering of multiple tests. Balance test safety, exposure to health care providers, and PPE resource use. Choose alternate tests with similar accuracy and less COVID-19 related safety concerns, if possible. Relate COVID-19 safety concerns of testing, PPE need, and resource use to the phase of the pandemic regionally and to institutional policies locally. |
Allow adequate time in between studies for sanitation. Adjust to slow throughput and workflow of laboratories due to COVID-19 precautions. Consider extended hours and opening laboratories on weekends to accommodate patient volumes and backlogs. Prioritize backlogs of patients according to clinical need and impact of test. |
COVID-19 = coronavirus disease 2019; PPE = personal protective equipment; TEE = transesophageal echocardiography.
Exposure Risk and Needed PPE During Cardiovascular Imaging in the COVID-19 Era
| CV Imaging | Exposure | Personal Protective Equipment | |
|---|---|---|---|
| No Symptoms Suggestive of COVID-19 | Confirmed/Suspected/Recovering COVID-19 | ||
| Cardiovascular CT/CMR | Droplet/contact | Surgical mask + gloves | Surgical mask + face shield |
| Pharmacological stress (SPECT/PET/CMR) | Droplet/contact | Surgical mask + gloves | Surgical mask + face shield |
| TTE/pharmacological stress echocardiography | Droplet with close contact (face-to-face) | Surgical mask + face shield | Surgical mask + face shield |
| Exercise test (SPECT/echocardiography/treadmill/MVO2) | Possible aerosol generating | Alternate test recommended (or MV | |
| TEE | Aerosol generating | N95 or N99 mask + face shield + appropriate surgical gown + gloves OR Reusable PAPR + surgical gown + gloves | |
CMR = cardiac magnetic resonance; CT = computed tomography; CV = cardiovascular; MVO2 = myocardial oxygen consumption during exercise; PAPR = powered air-purifying respirator; PET = positron emission tomography; SPECT = single-photon emission tomography; TTE = transthoracic echocardiography; other abbreviations as in Table 1.
For safety, test is best performed in a negative-pressure room with a good air exchange.
COVID-19 testing is currently at most 80% to 85% sensitive; an N95 or N99 mask or reusable PAPR is currently still advised for optimal protection.
Central IllustrationRole of Cardiovascular Imaging in the COVID-19 Era
Dynamic changes in the utilization and role of cardiovascular imaging during the different phases of the COVID-19 pandemic. COVID-19 = coronavirus disease 2019; CV = cardiovascular.
Role of Cardiovascular Imaging Specific to the COVID-19 Era: Minimize Risk, Reduce Resource Utilization, and Maximize Clinical Benefit
| Condition | Indication | TTE | TEE | CTA | CMR | Nuclear Cardiology (SPECT/PET) |
|---|---|---|---|---|---|---|
| CAD/myocardial injury | After STEMI intervention in selected COVID-19(+) | ++++ | x | x | + | x |
| Stable NSTEMI/ACS COVID-19(+) or suspected Low risk for COVID-19 | ++++ | x | ++ | + | + | |
| Chest pain with Clinical suspicion of CAD Known CAD | +++ | x | ++++ | ++++ | ++++ | |
| Cardiomyopathy/arrhythmias | New onset heart failure/cardiomyopathy | ++++ | + | +++ | ++++ | +++ |
| Myocardial viability imaging | + | x | + | ++++ | ++++ | |
| LAA evaluation prior to restoration of sinus rhythm | x | ++ | ++++ | ++ | x | |
| Valvular/structural | Endocarditis (native or prosthetic valve) | +++ | ++++ | ++ | ++ | ++ |
| Endocarditis, invasive complications (e.g., abscess, pseudoaneurysm) | ++ | ++++ | ++++ | ++ | ++ | |
| Prosthetic valve dysfunction (pannus, thrombus, calcification) | ++++ | ++ | ++++ | + | x | |
| Structural intervention planning TAVR, LAA occlusion Mitral and tricuspid valve repair | +++ | + | ++++ | ++ | x | |
| Masses/other | Cardiac mass evaluation | ++++ | ++ | +++ | ++++ | + |
| Pericardial diseases | ++++ | + | +++ | ++++ | x |
All clinical scenarios in the table assume no active or symptomatic COVID-19 disease, unless otherwise specified. 1+ to 4+ denote a measure of suitability for use during the peri–COVID-19 pandemic period and not necessarily a determination of any inherent diagnostic superiority of one modality over another or comparative efficacy. Strength of the indication and use of a test (1+ to 4+; X = rarely, if at all) and its traditional appropriateness for the clinical condition may be modified by the COVID-19 pandemic as noted. The table summarizes most common clinical indications relevant during the pandemic and cannot capture all nuances in clinical presentations which may affect appropriate test use.
(+) = positive; ACS = acute coronary syndrome; CAD = coronary artery disease; CTA = computed tomography angiography; LAA = left atrial appendage; NSTEMI = non–ST-segment elevation myocardial infarction; STEMI = ST-segment elevation myocardial infarction; TAVR = transaortic valve replacement; other abbreviations as in Tables 1 and 2.
Stress echocardiography has similar scoring to stress nuclear for the CAD and cardiomyopathy indications on this table. The stress type for all imaging modalities, where applicable, is pharmacological stress. Exercise stress has specific considerations during the active pandemic.
Reduced test use or priority compared with other tests because of COVID-19 risk exposure or need for more PPE. This reduction in use will undoubtedly lessen and be back to usual practices once the active infection rate of COVID-19 in the community is low and the pandemic is controlled.
Intensified medical therapy and conservative approach when possible in view of COVID-19 status.